MicroRNA-629-5p promotes osteosarcoma proliferation and migration by targeting caveolin 1

Chunsheng Gao,Weichun Guo,Huichao Yan,Junhua Zheng,Jun Gao,Ge Zeng

doi:10.1590/1414-431x202010474

Abstract

Osteosarcoma is a highly malignant tumor that occurs in the bone. Previous studies have shown that multiple microRNAs (miRNAs) regulate the development of osteosarcoma. This study aimed to explore the role of miR-629-5p and its target gene, caveolin 1 (CAV1), in osteosarcoma development. To analyze the expression of miR-629-5p and CAV1 mRNA in osteosarcoma tissues and cell lines, qRT-PCR analysis was performed. Dual-luciferase reporter experiments were subsequently performed to validate the relationship between CAV1 and miR-629-5p. CCK8 assay was used to measure osteosarcoma cell proliferation, and wound-healing assay was performed to study their migratory phenotype. Our findings revealed that miR-629-5p was overexpressed in osteosarcoma tissues and cells, and thereby enhanced cell proliferation and migration. Further, we validated that miR-629-5p targets CAV1 mRNA directly. CAV1 expression, which was negatively correlated with miR-629-5p expression, was found to be downregulated in osteosarcoma tissue samples. Moreover, our data showed that an increase in CAV1 level led to a decline in osteosarcoma cell proliferation and migration, which could be rescued by miR-629-5p upregulation. Overall, our study confirmed that miR-629-5p promoted osteosarcoma proliferation and migration by directly inhibiting CAV1.

Highlights

Osteosarcoma is a malignant bone tumor that typically develops in the knees [1]
We observed that the U6 CT values of HOS, U2OS, SJSA-1, and Saos2 were similar to those of hFOB1.19 (Supplementary Figure S1A and B). These results showed that U6 was stably expressed in osteosarcoma tissues and cell lines
We demonstrated that miR-629-5p and caveolin 1 (CAV1) played crucial roles in osteosarcoma development

Summary

Introduction

Osteosarcoma is a malignant bone tumor that typically develops in the knees [1]. Osteosarcoma is the most common type of bone cancer in children and adolescents under the age of 20, and is a life-threatening cancer [2,3]. Much progress has been made in decreasing osteosarcoma symptoms owing to the application of chemotherapy, radiotherapy, and new anti-tumor therapies [5,6,7]. The cure rate of high-risk osteosarcoma remains low due to drug resistance and metastasis [1]. These continue to be major challenges in the successful treatment of osteosarcoma. There is an urgent need for further research to identify new treatment modalities for osteosarcoma

Objectives

Methods

Results

Conclusion